These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19759250)

  • 41. Comparative analysis of the immunologic response induced by the Sterne 34F2 live spore Bacillus anthracis vaccine in a ruminant model.
    Ndumnego OC; Köhler SM; Crafford J; van Heerden H; Beyer W
    Vet Immunol Immunopathol; 2016 Oct; 178():14-21. PubMed ID: 27496738
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased long-term immunity to Bacillus anthracis protective antigen in mice immunized with a CIA06B-adjuvanted anthrax vaccine.
    Wui SR; Han JE; Kim YH; Rhie GE; Lee NG
    Arch Pharm Res; 2013 Apr; 36(4):464-71. PubMed ID: 23440578
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.
    Leffel EK; Bourdage JS; Williamson ED; Duchars M; Fuerst TR; Fusco PC
    Clin Vaccine Immunol; 2012 Aug; 19(8):1158-64. PubMed ID: 22695155
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain.
    Flick-Smith HC; Waters EL; Walker NJ; Miller J; Stagg AJ; Green M; Williamson ED
    Microb Pathog; 2005 Jan; 38(1):33-40. PubMed ID: 15652293
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bacillus subtilis spore vaccines displaying protective antigen induce functional antibodies and protective potency.
    Oh Y; Kim JA; Kim CH; Choi SK; Pan JG
    BMC Vet Res; 2020 Jul; 16(1):259. PubMed ID: 32723323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.
    Baillie LW; Huwar TB; Moore S; Mellado-Sanchez G; Rodriguez L; Neeson BN; Flick-Smith HC; Jenner DC; Atkins HS; Ingram RJ; Altmann DM; Nataro JP; Pasetti MF
    Vaccine; 2010 Sep; 28(41):6740-8. PubMed ID: 20691267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Poly-gamma-d-glutamic acid and protective antigen conjugate vaccines induce functional antibodies against the protective antigen and capsule of Bacillus anthracis in guinea-pigs and rabbits.
    Lee DY; Chun JH; Ha HJ; Park J; Kim BS; Oh HB; Rhie GE
    FEMS Immunol Med Microbiol; 2009 Nov; 57(2):165-72. PubMed ID: 19732139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.
    Peachman KK; Li Q; Matyas GR; Shivachandra SB; Lovchik J; Lyons RC; Alving CR; Rao VB; Rao M
    Clin Vaccine Immunol; 2012 Jan; 19(1):11-6. PubMed ID: 22089245
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity.
    Li ZN; Mueller SN; Ye L; Bu Z; Yang C; Ahmed R; Steinhauer DA
    J Virol; 2005 Aug; 79(15):10003-12. PubMed ID: 16014960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
    Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P
    Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.
    Nguyen ML; Crowe SR; Kurella S; Teryzan S; Cao B; Ballard JD; James JA; Farris AD
    Infect Immun; 2009 Jan; 77(1):162-9. PubMed ID: 18981257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of a novel multiepitope chimeric vaccine against anthrax.
    Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R
    Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection.
    Hepler RW; Kelly R; McNeely TB; Fan H; Losada MC; George HA; Woods A; Cope LD; Bansal A; Cook JC; Zang G; Cohen SL; Wei X; Keller PM; Leffel E; Joyce JG; Pitt L; Schultz LD; Jansen KU; Kurtz M
    Vaccine; 2006 Mar; 24(10):1501-14. PubMed ID: 16271808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recombinant GroEL enhances protective antigen-mediated protection against Bacillus anthracis spore challenge.
    Sinha K; Bhatnagar R
    Med Microbiol Immunol; 2013 Apr; 202(2):153-65. PubMed ID: 23263010
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques.
    Livingston BD; Little SF; Luxembourg A; Ellefsen B; Hannaman D
    Vaccine; 2010 Jan; 28(4):1056-61. PubMed ID: 19896452
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of three anthrax toxin neutralization assays.
    Ngundi MM; Meade BD; Lin TL; Tang WJ; Burns DL
    Clin Vaccine Immunol; 2010 Jun; 17(6):895-903. PubMed ID: 20375243
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.
    Albrecht MT; Li H; Williamson ED; LeButt CS; Flick-Smith HC; Quinn CP; Westra H; Galloway D; Mateczun A; Goldman S; Groen H; Baillie LW
    Infect Immun; 2007 Nov; 75(11):5425-33. PubMed ID: 17646360
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.
    Crowe SR; Garman L; Engler RJ; Farris AD; Ballard JD; Harley JB; James JA
    Vaccine; 2011 May; 29(20):3670-8. PubMed ID: 21420416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge.
    Lee JS; Hadjipanayis AG; Welkos SL
    Infect Immun; 2003 Mar; 71(3):1491-6. PubMed ID: 12595467
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intramuscular delivery of adenovirus serotype 5 vector expressing humanized protective antigen induces rapid protection against anthrax that may bypass intranasally originated preexisting adenovirus immunity.
    Wu S; Zhang Z; Yu R; Zhang J; Liu Y; Song X; Yi S; Liu J; Chen J; Yin Y; Xu J; Hou L; Chen W
    Clin Vaccine Immunol; 2014 Feb; 21(2):156-64. PubMed ID: 24307239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.